Novo Nordisk: positive CHMP opinion for obesity drug
(CercleFinance.com) - Novo Nordisk announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended extending the use of Saxenda for the treatment of obesity in teenagers (12 to 17 years old).
Over the past 20 years, the global prevalence of obesity in children and teenagers has doubled from one in 10 to one in five, and there are now over 124 million children and teenagers who are obese worldwide, it said.
The CHMP's opinion is based on the results of a phase III trial published last year in the New England Journal of Medicine. Novo Nordisk expects to receive the European Commission's decision on the labeling update for Saxenda within a few months.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
Over the past 20 years, the global prevalence of obesity in children and teenagers has doubled from one in 10 to one in five, and there are now over 124 million children and teenagers who are obese worldwide, it said.
The CHMP's opinion is based on the results of a phase III trial published last year in the New England Journal of Medicine. Novo Nordisk expects to receive the European Commission's decision on the labeling update for Saxenda within a few months.
Copyright (c) 2021 CercleFinance.com. All rights reserved.